Department of Gastrointestinal Surgery, St. Olavs Hospital, Trondheim University Hospital, 7006, Trondheim, Norway.
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
World J Surg Oncol. 2021 Jul 13;19(1):212. doi: 10.1186/s12957-021-02313-3.
Response evaluation following neoadjuvant chemotherapy (NAC) in gastric cancer is debated. The aim of this study was to investigate the value of UICC-downstaging as mode of response evaluation following a MAGIC-style regimen of NAC.
Retrospective, population-based study on consecutive patients with resectable gastric adenocarcinoma receiving NAC from 2007 to 2016. CT-scan was obtained at diagnosis (rTNM) and repeated following NAC (yrTNM) to evaluate response in terms of downstaging. Further, yrTNM stage was crosstabulated to pathologic stage (ypTNM) to depict correlation between radiologic and pathologic assessment.
Of 171 patients receiving NAC, 169 were available for response evaluation. For TNM-stages, 43% responded, 50% had stable disease and 7% progressed at CT. Crosstabulating yrTNM stage to ypTNM stage, 24% had concordant stages, with CT overstaging 38% and understaging 38% of the tumours, Cohen kappa ƙ = 0,06 (95%CI 0.004-0.12). Similar patterns of discordance were found for T-stages and N-stages separately. For M-category, restaging CT detected 12 patients with carcinomatosis, with an additional 14 diagnosed with carcinomatosis only at operation. No patient developed parenchymal or extra abdominal metastases, and none developed locally non-resectable tumour during delivery of NAC. Restaging CT with response evaluation was not able to stratify patients into groups of different long-term survival rates based on response mode.
Routine CT-scan following NAC is of limited value. Accuracy of CT staging compared to final pathologic stage is poor, and radiologic downstaging as measure of response evaluation is unreliable and unable to discriminate long-term survival rates based on response mode.
新辅助化疗(NAC)后疗效评估在胃癌中存在争议。本研究旨在探讨采用 MAGIC 方案 NAC 后,UICC 降级作为疗效评估模式的价值。
回顾性分析 2007 年至 2016 年连续接受 NAC 的可切除胃腺癌患者的人群研究。在诊断时(rTNM)和 NAC 后重复进行 CT 扫描,以根据降级情况评估反应。进一步将 yrTNM 分期与病理分期(ypTNM)进行交叉制表,以描述影像学和病理学评估之间的相关性。
在接受 NAC 的 171 例患者中,有 169 例可进行疗效评估。对于 TNM 分期,43%的患者有反应,50%的患者疾病稳定,7%的患者 CT 进展。将 yrTNM 分期与 ypTNM 分期交叉制表,24%的患者分期一致,CT 过度分期 38%,肿瘤分期不足 38%,Cohen kappa κ=0.06(95%CI 0.004-0.12)。T 分期和 N 分期分别也存在类似的不一致模式。对于 M 分期,重新分期 CT 检测到 12 例有癌转移患者,另有 14 例仅在手术时诊断为癌转移。没有患者发生实质或腹外转移,也没有患者在接受 NAC 期间发生局部不可切除的肿瘤。基于反应模式,重新分期 CT 不能对不同长期生存率的患者进行分层。
NAC 后常规 CT 扫描价值有限。与最终病理分期相比,CT 分期的准确性较差,作为反应评估指标的放射学降级不可靠,无法根据反应模式区分长期生存率。